Banco Comercial Português, S.A. informs about Interim report on the transactions conducted under the Share Buy-Back Programme
Attachment
Tag: GlobeNewswire
Conference Call Scheduled for Tuesday, November 3, 2026, at 8:30 a.m. ET
PALM BEACH GARDENS, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) — Great Elm Capital Corp. (the “Company” or “GECC”) (NASDAQ: GECC), a business development company, today announced that it will release its financial results for the third quarter ended September 30, 2026, after the close of market trading on Monday, November 2, 2026. The results will be discussed in a conference call on Tuesday, November 3, 2026, at 8:30 a.m. ET.
| Date/Time: | Tuesday, November 3, 2026 – 8:30 a.m. ET |
| Participant Dial-In Numbers: | |
| (United States): | (877) 407-0789 |
| (International): | (201) 689-8562 |
To access the call, please dial-in approximately five minutes before the start time and, when asked, provide the operator with passcode “GECC”. An accompanying slide presentation will be available in pdf format via the “Events and Presentations” section of Great Elm Capital Corp.’s website here after the issuance of the earnings release.
Webcast
The call and presentation will also be simultaneously webcast over the internet via the “Events and Presentations” section of GECC’s website or by clicking on the webcast link here.
About Great Elm Capital Corp.
GECC is an externally managed business development company that seeks to generate current income and capital appreciation by investing in debt and income generating equity securities, including investments in specialty finance businesses and CLOs. For additional information, please visit http://www.greatelmcc.com.
Media & Investor Contact:
Investor Relations
investorrelations@greatelmcap.com
Source: Great Elm Capital Corp.
Ress Life Investments
August Bournonvilles Passage 1
DK-1055 Copenhagen K
Denmark
CVR nr. 33593163
www.resslifeinvestments.com
To: Nasdaq Copenhagen
Date: 30 October 2026
Corporate Announcement 36/2026
Ress Life Investments A/S publishes Net Asset Value (NAV).
Ress Life Investments A/S publishes the Net Asset Value (NAV) per share as of 15 October 2026.
NAV per share in USD: 2748.20
The performance during the first half of October 0.00% in USD. The year-to-date net performance is 4.15% in USD.
Assets under management (AUM) are 227.6 million USD.
The NAV per share in EUR is published on the website of Nasdaq Copenhagen under the section AIF Companies and Funds, where the bid and ask prices are published. The daily NAV in EUR is calculated as the most recently published NAV in USD divided by the European Central Bank’s EUR/USD reference rate on the relevant day.
Questions related to this announcement can be made to the company’s AIF-manager, Finserve Nordic AB.
Contact person:
Gustaf Hagerud
gustaf.hagerud@finserve.se
Tel + 46 73 660 72 42
Note: The terms for subscription of shares, minimum subscription amount and redemption of shares are provided in the Articles of Association, Information Brochure and in the Key Information Document available on the Company’s website, www.resslifeinvestments.com.
Attachment
Singapore, Oct. 30, 2026 (GLOBE NEWSWIRE) — ChowChow Cloud International Holdings Limited (“ChowChow”, the “Company”) (NYSE American: CHOW) today announced the closing of its previously announced private placement.
As previously disclosed, on June 16, 2026, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an investor for the sale of 862,069 ordinary shares at $0.58 per share, for an aggregate purchase price of US$500,000.
Following the Company’s 1-for-10 reverse share split and redesignation, approved by shareholders on September 14, 2026 and effective October 23, 2026, these amounts were adjusted to 86,207 Class A Ordinary Shares at US$5.80 per share.
On October 26, 2026, the Company received the balance of the purchase price, completing payment of the full US$500,000.
On October 29, 2026, the transaction closed and the Company issued 86,207 restricted Class A Ordinary Shares to the investor.
About ChowChow Cloud International Holdings Limited
ChowChow Cloud is a pioneer in providing one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey from consulting, deployment and migration to cloud environment building and management. ChowChow Cloud was founded in December 2014 by a group of passionate and experienced professionals, who envisioned the potential of cloud technology to transform the way businesses of various sizes operate. Recognizing the growing need for digitization and the benefits that cloud technology could bring to businesses, ChowChow Cloud’s founders set out to create a company that would bridge the gap between cloud services providers and companies who seek to move to the cloud.
Forward-looking Statements
This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements give our current expectations, opinion, belief or forecasts of future events and performance. A statement identified by the use of forward-looking words including “will,” “may,” “expects,” “projects,” “anticipates,” “plans,” “believes,” “estimate,” “should,” and certain of the other foregoing statements may be deemed forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations, except as required by law.
For more information, please contact:
Investor Relations Team
ChowChow Cloud International Holdings Limited
Email: ir@chochowcloud.com
Heineken N.V. successfully places €1.0 billion of Notes
Amsterdam, 30 October 2026 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) announced that it has successfully placed €1.0 billion of Notes across two tranches today.
• €500 million 3-year Notes with a coupon of 3.750%, and
• €500 million 7-year Notes with a coupon of 4.125%.
The Notes will be issued under the Company’s Euro Medium Term Note Programme and will be listed on the Luxembourg Stock Exchange.
The proceeds from the Notes issuance will be used for general corporate purposes, including debt repayments. The maturity dates of the Notes are 10 November 2029 and 10 November 2033 respectively.
Goldman Sachs, ING, IMI-Intesa Sanpaolo, Santander, and Société Générale acted as active book runners.
| Enquiries | |||
| Media | Investors | |
| Christiaan Prins | Tristan van Strien | |
| Director of Global Communication | Global Director of Investor Relations | |
| Marlous den Bieman | Lennart Scholtus / Isabelle van Rongen | |
| Head of Media | Investor Relations Managers | |
| E-mail: pressoffice@heineken.com | E-mail: investors@heineken.com | |
| Tel: +31-20-5239355 | Tel: +31-20-5239590 |
Regulatory information
This press release is issued in connection with the disclosure and reporting obligations as set out in Article 5(1)(b) Regulation (EU) 596/2014 and Article 2(2) of the Commission Delegated Regulation (EU) 2016/1052 that contains technical standards for buyback programs.
Editorial information:
HEINEKEN is the world’s pioneering beer company. We are the leading developer and marketer of premium and non-alcoholic beer and cider brands. Led by the Heineken® brand, we have a portfolio of more than 340 international, regional, local, and specialty beers and ciders. With HEINEKEN’s over 87,000 employees, we brew the joy of true togetherness to inspire a better world. Our dream is to shape the future of beer and beyond to win the hearts of consumers. We are committed to innovation, long-term brand investment, disciplined sales execution, and focused cost management. Through “Brew a Better World”, sustainability is embedded in the business. HEINEKEN has a well-balanced geographic footprint with leadership positions in both developed and developing markets. We operate breweries, malteries, cider plants, and other production facilities in more than 70 countries. Most recent information is available on our Company’s website, and follow us on LinkedIn and Instagram.
Attachment
WOODCLIFF LAKE, N.J., Oct. 30, 2026 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “Amendment”) to its existing limited duration stockholder rights plan (as amended, the “Rights Plan”) to extend the duration of the Rights Plan by one year to October 30, 2027, effective immediately.
The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the trading price of the Company’s common stock. The amendment will have the effect of increasing the potential dilution an Acquiring Person would potentially face if the Rights Plan were triggered. Accordingly, the Rights Plan, as amended, is intended to enable all of the Company’s stockholders to have the opportunity to realize the long-term value of their investment and reduce the likelihood that any person or group gains control of the Company through open market accumulation or other means without appropriately compensating all stockholders or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of the Company and its stockholders.
The Board did not adopt the extension to the Rights Plan in response to a specific takeover threat. In addition, the Rights Plan does not prevent the Board from engaging with parties or accepting an acquisition proposal, if the Board believes that it is in the best interests of the Company and all of its stockholders.
The Rights Plan, as amended, will automatically expire on October 30, 2027, unless the rights are earlier redeemed or exchanged by the Company. The Rights will be exercisable only if a person or group (an “Acquiring Person”) acquires or launches a tender or exchange offer to acquire beneficial ownership (which includes certain synthetic equity interests) of 10% or more of Eagle’s outstanding common stock (15% in the case of a passive institutional investor as described in the Rights Plan). Any stockholders with beneficial ownership of Eagle’s outstanding common stock above the applicable threshold as of the time of the initial announcement of the Rights Plan on October 30, 2024 are grandfathered at their current ownership levels but are not permitted to increase their ownership without triggering the Rights Plan. Once the Rights become exercisable, pursuant to the Rights Plan, each Right will entitle its holder (other than any Acquiring Person, whose Rights will become void) to purchase, for $20.00, additional shares of Eagle’s common stock having a market value of twice such exercise price. In addition, the Rights Plan has customary flip-over and exchange features. Except as otherwise set forth in the Amendment, the terms of the Rights Plan are unchanged and remain in full force and effect.
Eagle’s stockholders do not need to take any further action with respect to the rights or the Rights Plan at this time.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.
Forward-Looking Statements
This press release contains “forward-looking statements” regarding future events or the Company’s future financial performance. These statements are not historical facts and may be identified by words such as “anticipate,” “will,” “would,” “could,” “may,” “intend,” “remain,” “regain,” “maintain,” “potential,” “prepare,” “expect,” “believe,” “plan,” “seek,” “continue,” “goal,” “estimate,” and similar expressions. They include statements regarding the impacts of adopting the Rights Plan, including its ability to protect stockholders’ ability to realize the long-term value of their investment and provide the Board with sufficient time to make informed judgments and act in the best interests of the Company and its stockholders; and the Company’s review of potential financing and other alternatives, including the types of arrangements or transactions it may pursue, the scope and timing of the review, the potential value of any arrangements or transactions and the review’s outcome. These statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include: global economic and political conditions, including geopolitical factors and conflicts; reliance on third parties to manufacture commercial supplies of the Company’s products and clinical supplies of its product candidates; delays or uncertainties in obtaining, or failure to obtain, regulatory approval of the Company’s or its partners’ product candidates; compliance with U.S. Food and Drug Administration, European Medicines Agency and other governmental agencies applicable to product approvals; changes in the regulatory environment and applicable laws and regulations; the Company’s ability to market and commercialize its products successfully; the success of its relationships with partners; limitations on trading of its common stock on the OTC Expert Market and impacts on its stock price and reputation; its ability to recruit, hire and retain key personnel; the outcome of litigation and other legal proceedings and the risk of additional proceedings; the strength and enforceability of the Company’s intellectual property rights or those of third parties; competition from pharmaceutical and biotechnology companies and generic entrants; unexpected safety or efficacy data from clinical trials; lower-than-expected clinical trial site activation or enrollment rates; risks inherent in drug development and clinical trials; inaccuracies in estimates or judgments relating to critical accounting policies or other estimates or projections; and other unanticipated factors that may affect the Company’s financial and business projections or cause actual results to differ materially from estimates and projections. Readers are cautioned not to place undue reliance on these statements, which speak only as of the date they are made. Except as required by law, the Company undertakes no obligation to update them to reflect subsequent events or circumstances.
CONTACT: Media Contact: Amy M. Hancock Senior Manager, Investor Relations ahancock@eagleus.com
GLENVIEW, Ill., Oct. 30, 2026 (GLOBE NEWSWIRE) — Illinois Tool Works Inc. (NYSE: ITW) today announced that its Board of Directors has declared a dividend on the company’s common stock of $1.72 per share for the fourth quarter of 2026. The dividend is payable on January 15, 2027 to shareholders of record at the close of business on December 31, 2026.
About ITW:
Founded in 1912, Illinois Tool Works Inc. (NYSE: ITW) is a Fortune 300 global multi-industry manufacturing leader with revenue of $16 billion in 2025. The company’s seven industry-leading segments leverage the unique ITW Business Model to drive solid growth with best-in-class margins and returns in markets where highly innovative, customer-focused solutions are required. ITW’s approximately 43,000 dedicated colleagues around the world thrive in the company’s decentralized and entrepreneurial culture. To learn more, please visit www.itw.com.
Investor Relations & Media Contact:
Erin Linnihan
Tel: 224.661.7431
investorrelations@itw.com | mediarelations@itw.com
TME Pharma Publishes Its Semi Annual Results and Half-Year Report
Berlin, Germany, October 30, 2026, 18:00 CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech-company with clinical assets for brain cancer and eye diseases, today publishes it results for the first half of the year, and its half-yearly report.
TME Pharma reported no revenue (€27k, H1 2025) and a net loss of €0,51M (2,1M loss, H1 2025). General and administrative expenses decreased 79% to €203k and research and development expenses decreased by 98%. Cash position on 30 June 2026 was €1,02M. As discussed at the Annual Shareholder’s Meeting in June 2025, the equity has fallen below the 50% threshold and became negative in the second quarter of 2025. As of June 2026 the equity remains negative for an amount of €2,61M. Under the current IFRS accounting standard, TME Pharma’s assets, like goodwill, raw materials and vials on stock are valued at €0. These assets can indeed represent value when agreements are successfully concluded with partners.
TME Pharma announced two significant developments after the balance sheet date:
- The debt repayment date was extended to June 30, 2028, and two new bond issuances were completed. As a result, financial visibility has been extended through Q2 2028 (Press release from October 26).
- An exclusive negotiation agreement was signed with Japanese company TMS Co., Ltd. to finalize a licensing agreement and further develop the flagship product NOX-A12 (Press release from October 29).
The semi-annual report is available on the website of TME Pharma.
Diede van den Ouden, CEO of TME Pharma, said:
“In the first half of the year, we focused primarily on discussions and negotiations with prospective partners. Although TME continues to pursue a policy of strict cost control, we had to incur expenses for legal counsel and due diligence, as well as to maintain the infrastructure of the GLORIA study. I am pleased that these efforts and investments have led to the October 29 announcement, in which we were able to announce an exclusivity agreement with the Japanese company TMS Co., Ltd.. The clear next operative objective of the collaboration with TMS is to enable the restart of the GLORIA study which is still “ready to go”.
TME Pharma shareholders will hopefully be able to benefit in various ways from a definitive agreement. TME will receive cash, and costs will drop dramatically, as the partner will assume all ongoing costs related to NOX-A12 (such as operational costs, consultants, and patents). Most importantly, however, significant potential value could be generated if the results of the upcoming restart of the GLORIA study are as positive as those already available to date.”
For more information, please contact:
TME Pharma N.V.
Diede van den Ouden, CEO
ir@tmepharma.com
www.tmepharma.com
About TME Pharma
TME Pharma is a biotechnology company with two assets with potential to be developed into novel therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. The Company’s two lead assets are:
- NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which has been studied (GLORIA Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. The US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe.
- NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), for ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect.
The Company is currently seeking opportunities to secure the financial resources to unlock the value of NOX-A12 and NOX-E36. These steps include:
- Finalizing the partnership with TMS Co., Ltd. For NOX-A12
- Raising funds from alternative sources to secure longer financial visibility and to minimize dilution for shareholders
- Seeking partners for NOX-E36, for example through licensing deals
- Pursuing stable, cash-generating business opportunities to achieve positive operational cash flow for the Company
- Leveraging tax loss carry forwards
About the GLORIA Study
The GLORIA (NCT04121455) ‘ready to go’-study is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy and bevacizumab in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy).
About the OPTIMUS Study
OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.
Further information can be found at: www.tmepharma.com.
Disclaimer
Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain “forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.
Attachments
Mise à disposition du rapport financier semestriel 2026
Paris, le 30 octobre 2026, 18h00 CET, Audacia (FR00140059B5 – ALAUD), entreprise de private equity spécialisée dans le Capital Développement, le Capital Immobilier et le Capital Innovation, reconnue pour ses thèses d’investissement pionnières, notamment dans le Quantique et le New Space, annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son rapport financier semestriel au 30 juin 2026.
Le rapport financier semestriel 2026 est disponible sur le site Investisseurs d’Audacia, dans la rubrique Rapports et Résultats, ainsi que sur le site d’Euronext.
***
A propos d’AUDACIA
Fondée en 2006 par Charles Beigbeder, Audacia est une société de gestion indépendante cotée sur Euronext Growth Paris (ISIN : FR00140059B5 ; ticker : ALAUD), éligible au PEA et au PEA-PME. Le groupe propose des solutions d’investissement diversifiées autour de trois métiers : Capital Développement, Capital Immobilier et Capital Innovation. Ce dernier couvre notamment les technologies quantiques, le New Space, la décarbonation, le nouveau nucléaire et la défense. Depuis sa création, Audacia a investi plus d’un milliard d’euros dans plus de 400 entreprises.
Mnémonique : ALAUD
Code ISIN : FR00140059B5
Euronext Growth Paris
CONTACTS
| Éléonore de Rose eleonore.derose@audacia.fr +33 1 56 43 48 00 / +33 6 62 64 40 53 |
|
| Dusan Oresansky / Pierre Laurent Relations investisseurs audacia@newcap.eu +33 1 44 71 94 92 |
Attachments
PRESS RELEASE
REGULATED INFORMATION
Brussels, 30 October 2026, 5:55 PM
Nextensa NV/SA: Information on the total number of voting rights and shares
In application of article 15 of the Law of 2 May 2007 on disclosure of major shareholdings, Nextensa (the ‘Company’) announces the following information following the obtaining of double voting rights attached to registered shares.
Situation on 30 October 2026:
- Total capital : EUR 111,856,017.40
- Total number of securities carrying voting rights: 10,171,130
- Number of securities with double voting rights: 6,437,755(1)
Total number of voting rights (= the denominator): 16,608,885(2)
On the basis of this information, the shareholders of the Company can verify whether they are above or below one of the thresholds of 3% (threshold set by the articles of association), 5%, 10%, and so on (in multiples of five) of the total voting rights, and whether there is therefore an obligation to notify the company that they have exceeded this threshold.
(1) 204 of the 6,437,755 shares that in principle give the right to double voting rights are held by a subsidiary of the Company. The voting rights attached to these 204 shares have therefore been suspended.
(2) The voting rights attached to the treasury shares (currently: 65,000 shares) are suspended in accordance with article 7:217, §1 of the Code of companies and associations.
For more information
Tim Rens | Chief Financial Officer
Nextensa NV/SA | 0436.323.915 (RLE Brussels, Dutch-speaking division)
Gare Maritime, Picardstraat 11, B505, 1000 Brussels
+32 2 882 10 08 | investor.relations@nextensa.eu
www.nextensa.eu
About Nextensa
Nextensa is a mixed real estate investor and developer.
The company’s investment portfolio is divided between the Grand Duchy of Luxembourg (31%), Belgium (54%) and Austria (15%); its total value as at 30/06/2026 was approximately €1.1 billion.
As a developer, Nextensa is primarily active in shaping large urban developments. At Tour & Taxis (development of over 350,000 m²) in Brussels, Nextensa is building a mixed real estate portfolio consisting of a revaluation of iconic buildings and new constructions. In Luxembourg (Cloche d’Or), it is working in partnership on a major urban extension of more than 400,000 m² consisting of offices, retail and residential buildings.
The company is listed on Euronext Brussels and has a market capitalisation of €462 M (value 30/06/2026).
Attachment
